Select region:

Clinical trials located in

Kiel

Kiel city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Kiel, located in northern Germany, is the capital city of Schleswig-Holstein. Founded in 1233, it boasts a rich maritime history, being a significant Baltic Sea port and the annual host of Kiel Week, the world’s largest sailing event. The city is also known for its role in submarine construction, both during World War II and in modern times. Kiel’s geographical position at the end of the Kiel Canal, the busiest artificial waterway in the world, significantly contributes to its importance in maritime trade and naval history.

  • CT-EU-00041182

    Exploring the safety of seladelpar in treating primary biliary cholangitis

    This is a long-term study on a drug named seladelpar for people with a liver disease called Primary Biliary Cholangitis (PBC). The main goal is to see if this drug is safe and easy for patients with PBC to use over a long period. A secondary goal is to see if seladelpar can effectively treat PBC and improve the patient’s quality of life. The study will track a few things, like if there are changes in the patient’s liver health which may lead to hospitalization or if the patient’s liver enzymes like alkaline phosphate and bilirubin level normalize or not after taking this drug.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    AustriaGermanySpainUnited Kingdom
  • Treating post-COVID heart issues with Prednisolone and Losartan

    This study looks at heart problems caused by Covid-19. Sometimes people who have had the virus continue to experience symptoms after they recover. This is called “long COVID.” One of the symptoms is heart problems. The heart is an important organ with high oxygen requirements and may be damaged in “long Covid-19”. These heart problems can cause shortness of breath, chest pain and palpitations. In the study, researchers will look at the use of two drugs – losartan and prednisolone – to treat these symptoms. People who have had Covid-19 and have such symptoms can take part in the research. Patients will receive medication or a placebo for 16 weeks. Scientists will track changes in heart function and symptoms to see if the treatment is working.

    AustriaGermany
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Study relating to new treatment for ovarian cancer

    This is a study for patients who have ovarian, fallopian tube, or primary peritoneal cancer that has resisted platinum-based treatments. The main goal is to see how well two drugs, Nemvaleukin Alfa and Pembrolizumab, work together compared to other chemotherapy treatments that the doctor chooses. Patients will be picked randomly by a computer to receive either the two-drug combo, one of the two drugs alone, or other chemo drugs, such as doxorubicin, paclitaxel, topotecan, or gemcitabine. This study is open, which means everyone will know which treatment is being given.

    AustriaBelgiumCzechiaFranceGermanyItalySpainUnited Kingdom
  • Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    BelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    AustriaBelgiumFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • R-Pola-Glo therapy for aggressive B-cell lymphoma

    This clinical study tests a new treatment combination called R-Pola-Glo for elderly or medically unfit patients with untreated aggressive B-cell lymphoma. It involves the anti-CD20 antibody rituximab with polatuzumab vedotin and glofitamab, aiming to develop a less intense chemotherapy option. The trial, enrolling 80 participants, will assess the effectiveness and safety of this therapy, which could be crucial for those ineligible for standard treatment due to age or health.

    AustriaGermany
  • Exploring new treatment for advanced melanoma

    In this research, the researchers are examining a mix of fianlimab and cemiplimab as a potential treatment for a type of skin cancer called melanoma that is in an advanced stage or has spread to other parts of the body. It is important to see if this new medication is better than a current treatment, called pembrolizumab, in slowing down the growth of the disease. The main aim is to see how they respond to treatment, and the contribution of each drug in the mix. Additionally, the researchers will see if the drug triggers any reaction from the body’s immune system, assess how the two-drug regimen affects the patient’s physical activity, the role they play in their lives, overall health, and life quality.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Testing the effect of the new drug on Crohn’s Disease

    This study is exploring a new medication for Crohn’s disease, an ailment of the gut. The medication, known as BI 706321, is given alongside another medication called Ustekinumab that is already used to treat Crohn’s. The trial is conducted to see if this combination helps to manage the disease better. Participants will be split into two groups. One group will be given the new medication and the other will receive a placebo, alongside Ustekinumab. Participating in this study will last for 1 year. During this time, participants will have about 13 visits to the clinic. Some visits will involve a colonoscopy where doctors look at the intestine’s condition. Their findings will help doctors understand if the new treatment is working.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandSpain
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    BelgiumFranceGermanyItalyNetherlandsPolandSpain
  • Study of etrasimod in treating intense ulcerative colitis

    This study is a follow-up to previous research for the treatment of people with moderate to serious ulcerative colitis (UC). UC is a condition that inflames the large intestine and causes sores on the inside. The study will monitor the effects and safety of a medicine called etrasimod. This research is for people who have been part of past research trials and wish to continue treatment. Doctors will track a few things like side effects and how the medicine affects the disease in ways they have designed.

    BulgariaCzechiaFranceGermanyHungaryItalyPoland
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    BelgiumCzechiaGermanyHungaryItalyPolandRomaniaSlovakiaSpainUnited Kingdom
  • Studying rimegepant’s effectiveness on Migraine

    This study is testing a new treatment, rimegepant, for adults with migraines who cannot take traditional migraine medications, such as triptans, possibly due to reasons like having a heart condition. The research aims to evaluate the effectiveness and tolerability of rimegepant over a 12-week period. Participants will be asked to rate their headache pain on a scale ranging from 0 (no pain) to 3 (severe pain) as one of the methods to assess the treatment’s impact.

    AustriaBelgiumDenmarkFinlandFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Fenfluramine Hydrochloride study for seizure control in cyclin-dependent kinase like-5 (CDKL5)

    This is studying a new substance called Fenfluramine Hydrochloride (ZX008) in children and adults experiencing seizures with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD). The research has two parts. In the first part, lasting 20 weeks, some participants receive the new drug, while others receive a placebo (inactive substance). This part aims to determine if ZX008 is effective and safe. The second part lasts 54 weeks and is open-label, meaning everyone is aware they are receiving the active drug. It helps assess long-term effects. If participants complete the first part, they can enroll in the second part, including an open-label treatment period (52 weeks) and a taper period (2 weeks).

    AustriaBelgiumGermanyNetherlandsPortugalSpainUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Test of Venetoclax and Obinutuzumab on Chronic Lymphocytic Leukemia

    This study involves adults diagnosed with chronic lymphocytic leukemia (CLL), the most common type of blood cancer, who have relapsed after previous treatment. The study looked at a retreatment approach using two drugs: Venetoclax, an oral pill already approved for the treatment of CLL, and Obinutuzumab, a drug given intravenously. Participants will receive both drugs for 6 cycles of 28 days each, followed by Venetoclax alone for an additional 6 to 18 cycles. There will be regular tests and checks to monitor disease activity and any potential side effects. The study will involve around 75 adults from around the world who have previously been treated with Venetoclax in combination with a specific antibody medicine. To measure the success of the study, researchers will closely monitor the reduction in disease symptoms in response to treatment.

    AustriaBulgariaGermanyItalyRomaniaSpain
  • Comparing idecabtagene vicleucel and lenalidomide therapy for Multiple Myeloma

    This study involves the comparison of two treatments to assess their effectiveness, safety, and tolerability in adults with multiple myeloma who did not achieve complete recovery after a stem cell transplant. One treatment, referred to as ‘ide-cel’ (idecabtagene vicleucel), is administered in combination with another medication called lenalidomide. The alternative treatment involves the use of lenalidomide alone. The study is an open experiment, meaning the assigned treatment is known. The primary objectives include evaluating the efficacy of the treatments, assessing their safety, and gauging the participants’ tolerance. Additionally, the study will monitor general well-being, considering factors such as strength, fatigue, pain, and any symptoms or side effects experienced.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNorwayPolandRomaniaSpainUnited Kingdom

See more clinical trials in other cities in Germany:

.